Key Highlights
- AEON shares rose 5.62% pre-market to $0.20, following Friday's 0.52% decline to $0.19.
- Expanded peptide-mapping analysis increased sequence coverage of the active neurotoxin from approximately 93% to 98%.
- The analysis showed 100% amino acid identity across all regions analyzed between ABP-450 and BOTOX.
- The company expects FDA feedback from a planned Type 2b biosimilar development meeting in the second half of 2026.
Expanded Structural Data Supports Biosimilar Program
AEON Biopharma, Inc. (NYSE American:AEON) shares rose in pre-market trading after the company announced final, expanded primary structure results supporting the molecular similarity of its lead candidate ABP-450 to BOTOX. The expanded analysis achieved 98% sequence coverage of the active botulinum neurotoxin, up from approximately 93% previously, with 100% amino acid identity across every region analyzed.
AEON Biopharma is a biopharmaceutical company headquartered in Aliso Viejo, California, advancing ABP-450 as a biosimilar to BOTOX for therapeutic use, targeting full-label U.S. market entry into a therapeutic neurotoxin market that exceeds $3 billion annually. ABP-450 is the same botulinum toxin complex approved and marketed for cosmetic indications under the name Jeuveau by another company.
Preliminary disulfide bond characterization identified the same interchain disulfide bond connecting the light and heavy chains in both ABP-450 and BOTOX across all tested lots, representing approximately 99% of total species in each product. Because this covalent connection is essential to the toxin's biological activity, its presence at the same position in both products is consistent with previously reported similar potency between the two.
FDA Pathway Progresses Toward Next Milestone
AEON Biopharma carries a market Capitalization of approximately $8.48 million, reflecting its status as a micro-cap biopharmaceutical company. The stock does not currently report a forward or trailing price-to-earnings ratio, with Earnings per share at negative $5.15. The stock's 52-week range spans $0.18 to $1.45.
In March 2026, AEON reported results from an earlier FDA meeting in which the agency reviewed the company's proposed analytical similarity strategy under the biosimilar approval pathway and provided constructive feedback on its development approach. The company now looks ahead to a planned Type 2b meeting with the FDA in the second half of 2026, which is expected to help inform the next phase of development, including clinical pharmacology and comparative clinical study requirements.
Analytical Progress Builds Toward Regulatory Clarity
AEON Biopharma's pre-market gain reflects investor optimism following meaningful progress in building the molecular identity package supporting ABP-450's biosimilarity to BOTOX. Investors will likely watch closely for FDA feedback from the upcoming Type 2b meeting as the next major milestone in the company's development pathway.






Please wait processing your request...